The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the U.K. Perspective.
 
Ramon Andrade De Mello
Honoraria - Astellas Pharma; AstraZeneca; Merck Serono; Novartis; Novartis
Consulting or Advisory Role - MSD Oncology; Pfizer; Zodiac Pharma
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; BMS Brazil; Merck; Pierre Fabre; Roche
 
Emili Ayoub
No Relationships to Disclose
 
Pedro Castelo-Branco
No Relationships to Disclose
 
Victor Andre De Almeida Zia
Employment - Zodiac Pharma
 
Andre Savio
No Relationships to Disclose
 
Daniel Humberto Pozza
No Relationships to Disclose
 
Hakaru Tadokoro
No Relationships to Disclose
 
Nelson Teich
Employment - United Health Group
Honoraria - AstraZeneca; Libbs; Novartis; Roche
Consulting or Advisory Role - Libbs